In:
Future Microbiology, Future Medicine Ltd, Vol. 17, No. 5 ( 2022-03), p. 339-350
Abstract:
Aims: Ivermectin is a safe, inexpensive and effective early COVID-19 treatment validated in 20+ random, controlled trials. Having developed combination therapies for Helicobacter pylori, the authors present a highly effective COVID-19 therapeutic combination, stemming from clinical observations. Patients & methods: In 24 COVID-19 subjects refusing hospitalization with high-risk features, hypoxia and untreated moderate to severe symptoms averaging 9 days, the authors administered this novel combination of ivermectin, doxycycline, zinc and vitamins D and C. Results & conclusions: All subjects resolved symptoms (in 11 days on average), and oxygen saturation improved in 24 h (87.4% to 93.1%; p = 0.001). There were no hospitalizations or deaths, less than (p 〈 0.002 or 0.05, respectively) background-matched CDC database controls. Triple combination therapy is safe and effective even when used in outpatients with moderate to severe symptoms. Clinical Trial Registration: NCT04482686 ( ClinicalTrial.gov )
Type of Medium:
Online Resource
ISSN:
1746-0913
,
1746-0921
DOI:
10.2217/fmb-2022-0014
Language:
English
Publisher:
Future Medicine Ltd
Publication Date:
2022
SSG:
12
